{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:04:10Z","timestamp":1781129050274,"version":"3.54.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010950","name":"Science and Technology Department, Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Lung adenocarcinoma with the classical EGFR 19 deletion and exon 21 L858R point mutations has exhibited good responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, the sensitivity of uncommon EGFR exon 20 insertion mutation to third-generation EGFR-TKIs has not been determined. Although emerging targeted therapies for EGFR exon 20 insertion mutation have been reported in recent years, such patients still have a poorer prognosis than those with typical or wild-type EGFR mutations.<\/jats:p><jats:p><jats:bold>Case summary:<\/jats:bold> Here, we report the case of a 57-year-old man with advanced non-small cell lung cancer (NSCLC) with a rare EGFR exon 20 N771_P772insH mutation. The patient was treated with furmonertinib as second-line therapy. Although his pleural effusion was more than before that during treatment, various examination results showed that the pleural effusion was closely related to hypoproteinemia; thus, local progression was not considered. His cough was significantly alleviated, and the dose was well tolerated. The patient was evaluated for a remarkable progression-free survival (PFS) of 10.0 months, a duration of response (DOR) of 8.0 months, and an overall survival (OS) of 22.0 months, which had not previously been achieved.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The present study indicated that furmonertinib might be a good treatment option for first-line progressive NSCLC patients with EGFR exon 20 insertion mutation.<\/jats:p>","DOI":"10.3389\/fphar.2022.964606","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:07:38Z","timestamp":1660716458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuzhou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaomei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyue","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/annonc\/mdt418","article-title":"Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: A multicentre observational study by the French ERMETIC-IFCT network","volume":"25","author":"Beau-Faller","year":"2014","journal-title":"Ann. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca. Cancer J. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0247620","DOI":"10.1371\/journal.pone.0247620","article-title":"Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review","volume":"16","author":"Burnett","year":"2021","journal-title":"PLoS One"},{"key":"B4","unstructured":"Phase Ib study of FURMONERTINIB in patients with NSCLC having exon 202021"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s40265-021-01588-w","article-title":"Furmonertinib: First approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1158\/1535-7163.MCT-17-0758","article-title":"Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions","volume":"17","author":"Floc'h","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S964","DOI":"10.1016\/j.annonc.2021.08.1815","article-title":"1210P Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)","volume":"32","author":"Han","year":"2021","journal-title":"Ann. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"24549","DOI":"10.3390\/ijms141224549","article-title":"EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features","volume":"14","author":"Lai","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial","volume":"40","author":"Le","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/cas.14277","article-title":"Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study","volume":"111","author":"Lei","year":"2020","journal-title":"Cancer Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1097\/JTO.0b013e3182614a9d","article-title":"Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations","volume":"7","author":"Lund-Iversen","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s40265-021-01632-9","article-title":"Mobocertinib: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41401-021-00667-8","article-title":"Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans","volume":"43","author":"Meng","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"B15","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1002\/cncr.29493","article-title":"Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib","volume":"121","author":"Naidoo","year":"2015","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"abstr 9015","DOI":"10.1200\/JCO.2022.40.16_suppl.9015","article-title":"9015 Antitumor activity of sunvozertinibin NSCLCpatientswith EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures","volume":"40","author":"Pasi","year":"2022","journal-title":"Am. Clin."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S862","DOI":"10.1016\/j.annonc.2020.08.1659","article-title":"1345P - preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)","volume":"31","author":"Piotrowska1","year":"2020","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejca.2021.02.038","article-title":"Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program","volume":"149","author":"Prelaj","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.lungcan.2007.06.024","article-title":"EGFR exon 20 insertion mutation in Japanese lung cancer","volume":"58","author":"Sasaki","year":"2007","journal-title":"Lung Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.cllc.2021.07.001","article-title":"EGFR exon 20 insertion NSCLC and response to platinum-based chemotherapy","volume":"23","author":"Shah","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","article-title":"Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation","volume":"15","author":"Shi","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.annonc.2022.02.010","article-title":"1O - furmonertinib versus gefitinib in treatment-na\u00efve EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG)","volume":"33","author":"Shi1","year":"2022","journal-title":"Ann. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-021-01561-7","article-title":"Amivantamab: First approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1016\/j.cllc.2019.06.018","article-title":"Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations","volume":"20","author":"Wu","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41401-021-00692-7","article-title":"Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes","volume":"43","author":"Wu","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e21063","DOI":"10.1200\/JCO.2022.40.16_suppl.e21063","article-title":"e21063 Short-term efficacyof furmonertinib in treatmentof NSCLCpatientswith EGFRexon20insertion","volume":"40","author":"XiaoyueZhou","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2016.01.018","article-title":"EGFR tyrosine kinase inhibitor (tki) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China","volume":"96","author":"Xu","year":"2016","journal-title":"Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2020.03.014","article-title":"EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study","volume":"145","author":"Yang","year":"2020","journal-title":"Lung Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.lungcan.2021.10.006","article-title":"A phase I\/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer","volume":"162","author":"Yasuda","year":"2021","journal-title":"Lung Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"abstr 9007","DOI":"10.1200\/JCO.2022.40.16_suppl.9007","article-title":"9007 Phase (Ph) 1\/2a study of CLN-081in patients(pts) with NSCLCwith EGFR exon 20insertionmutations(Ins20)","volume":"40","author":"Yu","year":"2022","journal-title":"Am. Clin."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e214761","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1\/2 open-label nonrandomized clinical trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.964606\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:07:42Z","timestamp":1660716462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.964606\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":37,"alternative-id":["10.3389\/fphar.2022.964606"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.964606","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"article-number":"964606"}}